Stock 600276 JIANGSU HENGRUI MEDICINE CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Jiangsu Hengrui Medicine Co., Ltd.

Equities

600276

CNE0000014W7

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-07-14 pm EDT 		5-day change 1st Jan Change
40.78 CNY -1.19% Intraday chart for Jiangsu Hengrui Medicine Co., Ltd. +4.00% -9.84%
Jul. 08 Hengrui Medicine Gets Inspection Clearance from Jiangsu Province's Drug Regulator MT
Jul. 05 Jiangsu Hengrui Medicine Gets Clinical Trial Approval for Pulmonary Fibrosis Drug MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Elevar Therapeutics Reports Plans for Near-Term Resubmission of NDA for First-Line Treatment Option for Unresectable Hepatocellular Carcinoma Following Type a FDA Meeting
AQ
Hengrui Medicine Gets Inspection Clearance from Jiangsu Province's Drug Regulator
MT
Jiangsu Hengrui Medicine Gets Clinical Trial Approval for Pulmonary Fibrosis Drug
MT
CStone Pharmaceuticals Grants Exclusive Promotion Rights for Tumor Drug in China to Jiangsu Hengrui Medicine
MT
Voluntary Announcement - CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals Co., Ltd Enter into an Exclusive Promotion Agreement of AYVAKIT® (avapritinib tablets) in Mainland China
CI
Jiangsu Hengrui Medicine Gets US FDA Approval for Anesthetic; Shares Rise 4%
MT
Pacira BioSciences Shares Tumble as FDA Approves Exparel Generic
DJ
Tranche Update on Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback Plan announced on May 15, 2024.
CI
Hengrui Pharmaceuticals, Subsidiary Get Regulatory Nod to Test Two Drugs
MT
Hengrui Pharma Units Get China Nod for Clinical Trial of Tumor Drug
MT
Hengrui Pharmaceuticals Gets Nod to Trial Vitiligo Drug
MT
China Grants Clinical Trial Approval for Anti-Cancer Injections
MT
Hengrui Pharma Gets China Drug Registration Certificate for Ovarian, Fallopian Tube Cancer Drugs
MT
Hengrui Pharma Misses US FDA Approval for Cancer Injection
MT
Hengrui Pharmaceuticals' Unit Gets Nod to Trial SHR-1905 Injection
MT
Hengrui Grants Rights to Bain Capital-Backed Company for Anti-Diabetes Treatment
MT
Hengrui Pharmaceuticals to Resubmit Marketing Application for Liver Cancer Drug Combination to US FDA
MT
Hengrui Pharmaceuticals Plans Up to 1.2 Billion Yuan Share Buyback
MT
Tranche Update on Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023.
CI
Jiangsu Hengrui Medicine Co., Ltd. announces an Equity Buyback for CNY 1,200 million worth of its shares.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600276 Stock
  4. News Jiangsu Hengrui Medicine Co., Ltd.